ABSTRACT
The frequency and description of side effects secondary to the subcutaneous application of SPf66 malaria vaccine and placebo are reported for each dose of application in the participants of the vaccine efficacy trial in Brazil. Side effects evaluated two hours after each application were detected in 8.0 per cent, 30.2 per cent and 8.8 per cent, for the 1st, 2nd and 3rd dose, respectively, in the SPf66 group, and in 7.0 per cent, 8.5 per cent and 2.9 per cent in the placebo group. Local reactions such as mild inflammation, nodule and pain or erythema frequently accompanied by pruritus were the most common reactions detected in both groups (3.8 per cent, 29.1 per cent and 8.5 per cent in the SPf66 group and 4.0 per cent, 7.6 per cent and 2.5 per cent in the placebo group). Among vaccinees, local side effects after the 2nd dose were more frequent in females. Systemic side effects were expressed mainly through general symptoms referred by the participants and were most frequent after the 1st dose in both groups (4.3 per cent in the SPf66 group and 3.0 per cent in the placebo group). Muscle aches and fever were referred by few participants. No severe adverse reactions were detected for either dose of application or group.
Subject(s)
Male , Middle Aged , Adolescent , Adult , Animals , Child , Female , Humans , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Malaria Vaccines/adverse effects , Double-Blind MethodABSTRACT
This paper describes the study population and the study design of the phase III field trial of the SPf66 vaccine in Brazil. Assessment of validity and precision principles necessary for the appropriate evaluation of the protective effect of the vaccine are discussed, as well as the results of the preliminary analyses of the gathered data. The analytical approach for the estimation of the protective effect of the vaccine is presented. This paper provides the conceptual framework for future publications.
Subject(s)
Humans , Male , Female , Animals , Adult , Adolescent , Child , Middle Aged , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Malaria Vaccines/immunology , Vaccines, Synthetic/immunology , Brazil/epidemiology , Clinical Trials, Phase III as Topic , Disease Reservoirs , Malaria, Falciparum/mortality , Malaria, Falciparum/prevention & control , Rural Population/statistics & numerical data , Reproducibility of Results , Research Design , SurvivorsABSTRACT
Os autores descrevem a ocorrencia de um surto de dengue em Boa Vista, Territorio Federal de Roraima em final de 1981 e inicio de 1982. O numero estimado de casos elevou-se a 7000, tendo sido identificados virus dos tipos 1 e 4 em uma amostra populacional. Essa e a primeira descricao de ocorrencia de um surto de dengue no Brasil
Subject(s)
Humans , Dengue , Disease Outbreaks , BrazilABSTRACT
A febre amarela silvestre pode comprometer o homem que, no Brasil, penetra nas regioes de mata, na bacia do Rio Amazonas (zonas rurais da Regiao Amazonica e Centro -Oeste). Nesta revisao e dada enfase especial ao estado atual da febre amarela no Brasil, tendo em conta registros da Divisao de Febre Amarela da Superintendencia de Campanhas de Saude Publica do Ministerio da Saude (numero de casos anuais, media mensal, distribuicao etaria e por sexo), ficando evidente que o homem jovem que por atividade laboral ou de lazer adentra nestas regioes de mata esta mais exposto de contrair a febre amarela. Sao analisados tambem aspectos do Programa Nacional de Controle da Febre Amarela (vacinacao; vigilancia epidemiologica; erradicacao do Aedes aegypti das areas reinfestadas; vigilancia anti-aegypti nas areas nao infestadas), assim como os problemas e perspectivas inerentes ao controle da febre amarela no Brasil